Polymyalgia rheumatica shows metabolomic alterations that are further altered by glucocorticoid treatment: Identification of metabolic correlates of fatigue.
Manning JE. et al, (2024), Journal of autoimmunity, 147
Vasculitic neuropathy-related disability, pain, quality of life, and autonomic symptoms: A survey of 312 patients.
Collins MP. et al, (2024), Rheumatology (Oxford)
2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis
Grayson PC. et al, (2022), Arthritis & Rheumatology, 74, 1872 - 1880
2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis
Ponte C. et al, (2022), Arthritis & Rheumatology, 74, 1881 - 1889
2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis.
Grayson PC. et al, (2022), Arthritis & rheumatology (Hoboken, N.J.)
2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis.
Ponte C. et al, (2022), Arthritis & rheumatology (Hoboken, N.J.)
2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis.
Ponte C. et al, (2022), Annals of the rheumatic diseases
2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis.
Grayson PC. et al, (2022), Annals of the rheumatic diseases
Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis.
Gribbons KB. et al, (2020), Arthritis care & research, 72, 1615 - 1624
Experience from the first UK inter-regional specialist multidisciplinary meeting in the diagnosis and management of IgG4-related disease.
Goodchild G. et al, (2020), Clinical medicine (London, England), 20, e32 - e39
Early development of new cardiovascular risk factors in the systemic vasculitides.
Monti S. et al, (2020), Clinical and experimental rheumatology, 38 Suppl 124, 126 - 134
2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
Hellmich B. et al, (2020), Annals of the rheumatic diseases, 79, 19 - 30
Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides: Insights from the DCVAS study.
Bischof A. et al, (2019), Neurology(R) neuroimmunology & neuroinflammation, 6
Rheumatoid factor testing in Spanish primary care: A population-based cohort study including 4.8 million subjects and almost half a million measurements
Morsley K. et al, (2019), Reumatología Clínica, 15, 350 - 354
Identification of Novel Adenosine Deaminase 2 Gene Variants and Varied Clinical Phenotype in Pediatric Vasculitis.
Gibson KM. et al, (2019), Arthritis & rheumatology (Hoboken, N.J.), 71, 1747 - 1755
Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis.
Tomasson G. et al, (2019), The Journal of rheumatology, 46, 928 - 934
Giant cell arteritis: new concepts, treatments and the unmet need that remains
Coath F. et al, (2019), Rheumatology, 58, 1123 - 1125
Giant cell arteritis: new concepts, treatments and the unmet need that remains.
Coath F. et al, (2019), Rheumatology (Oxford, England), 58
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SIRUKUMAB IN THE TREATMENT OF PATIENTS WITH GIANT CELL ARTERITIS
Schmidt W. et al, (2019), ANNALS OF THE RHEUMATIC DISEASES, 78, 827 - 827
Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.
Jayne D. et al, (2019), Arthritis & rheumatology (Hoboken, N.J.), 71, 952 - 963